The case for & against
Bull & Bear analysis
Aquestive Therapeutics (NASDAQ:AQST) is a biopharmaceutical company specializing in developing and commercializing innovative therapeutics to treat serious medical conditions, particularly focusing on rare diseases and specialty markets. Positioned within the pharmaceutical industry, the company is transitioning into potentially groundbreaking territory with its upcoming NDA resubmission for Anaphylm™, a treatment for allergic reactions including anaphylaxis. As the company navigates through cash burn challenges and fluctuating market sentiments, its ability to gain regulatory approval is critical in establishing its presence in the allergy treatment market.
Bull says
- ↑Positive Anaphylm PK/usability studies bolster FDA approval prospects.
- ↑Q2 revenue $13.82M (+18% YoY) with FY guidance of $46–50M.
- ↑Non-GAAP EBITDA loss narrowed to $5.2M from $9.3M year-ago.
- ↑Cash position of $98.5M funds operations through NDA resubmission.
- ↑Analyst consensus “Buy” with $8.50 target signals ~80% upside.
- ↑Strong growth potential in allergy treatment market; efficiency improving.
Bear says
- ↓Net loss $22.9M in Q2 highlights persistent cash burn.
- ↓FY revenue guidance of $46–50M trails consensus $50.8M.
- ↓Negative profitability metrics indicate challenges generating returns.
- ↓High short interest reflects investor skepticism, risking selling pressure.
- ↓Valuation metrics suggest overvaluation absent projected growth.
- ↓Regulatory risks if FDA delays or rejects Anaphylm resubmission.
Investment themes with AQST
Drug development driving global healthcare solutions
Stocks with highest short interest
Earnings Call · Q2 2025 · Mgmt. Guidance